AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ascendis Pharma Reports Q2 Net Loss of €38.9 Million, Down from €109.4 Million in Same Period Last Year.
ByAinvest
Thursday, Aug 7, 2025 4:10 pm ET1min read
Ascendis Pharma reported a net loss of €38.9 million in Q2 2025, compared to a net loss of €109.4 million in the same period last year. The company's loss per share was €0.64 basic and €0.82 diluted.
Ascendis Pharma (NASDAQ: ASND) reported its second-quarter (Q2) 2025 financial results, showing significant improvements in revenue and operational efficiency compared to the same period last year. The company's total revenue for Q2 2025 was €158.0 million, up from €36.0 million in Q2 2024, representing a substantial 339% increase. This growth was primarily driven by commercial products, with YORVIPATH (palopegteriparatide) contributing €103.0 million and SKYTROFA (lonapegsomatropin) adding €50.7 million [1].Despite the significant increase in revenue, Ascendis Pharma reported a net loss of €38.9 million for Q2 2025, compared to a net loss of €109.4 million in the same period last year. This represents a 64.4% reduction in net loss, despite higher operating expenses. The company's loss per share was €0.64 basic and €0.82 diluted [1].
The reduction in net loss can be attributed to improved operational efficiency and commercial success. Research and development (R&D) expenses decreased by 13.8% to €72.0 million, primarily due to the maturity of clinical trials in their growth disorders portfolio. However, selling, general, and administrative (SG&A) expenses increased by 44.8% to €107.6 million, reflecting ongoing commercial expansion efforts [1].
Ascendis Pharma maintained a strong cash position of €494 million as of June 30, 2025, down from €560 million at the end of 2024. This 11.8% cash burn over six months appears reasonable given their commercial expansion and ongoing R&D investments [1].
The company's pipeline developments position it for continued growth. The FDA's priority review of TransCon CNP (navepegritide) for children with achondroplasia, with a PDUFA date of November 30, 2025, and SKYTROFA's U.S. approval for adult growth hormone deficiency treatment, are key milestones. Additionally, the promising interim results from the COACH trial for combination therapy further strengthen their growth disorders franchise [1].
References:
[1] https://www.stocktitan.net/news/ASND/ascendis-pharma-reports-second-quarter-2025-financial-uf8xwa0fvvkh.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet